GSK has begun the sale of some of its consumer health brands, hoping to raise around £1 billion before spinning off its consumer healthcare business, according to reports.

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

if Haleon's suite of consumer health products were performing outstandingly well, they would not have been spun out of GSK in the first place. Many of the products Haleon sells are older brands ...

The manufacturer, GSK, was going to stop manufacturing the brand-name medication in 2024 ... The FTC and others argued that ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids ...

We expect the company to benefit from a consumer shift in both developed and emerging markets toward higher-end beauty brands ... and vaccine space, GSK rejoins our list of best stocks to buy ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

Mumbai: On 12 November 2024, Fireside Ventures, an early-stage venture fund focused on consumer brands, appointed Adarsh ...

Haleon, the two-year-old CPG spinoff from GSK, is not only leading ... to Haleon’s pain relief brands, SeeMe also cited Kenvue’s Tylenol for prioritizing consumer wellness “through ...

Under his leadership, the North office was responsible for numerous global and Indian brands like, PepsiCo, Nestle, GSK, Hero ...